210 related articles for article (PubMed ID: 30657027)
41. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
[TBL] [Abstract][Full Text] [Related]
42. What is new in multiple sclerosis spasticity research? Poster session highlights.
Ghezzi A
Neurodegener Dis Manag; 2016 Dec; 6(6s):45-47. PubMed ID: 27874498
[TBL] [Abstract][Full Text] [Related]
43. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
44. What's new in multiple sclerosis spasticity research? Poster session highlights.
Linker R
Neurodegener Dis Manag; 2017 Nov; 7(6s):51-53. PubMed ID: 29143588
[TBL] [Abstract][Full Text] [Related]
45. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
46. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H
Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997
[TBL] [Abstract][Full Text] [Related]
47. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
48. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
[TBL] [Abstract][Full Text] [Related]
49. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
[TBL] [Abstract][Full Text] [Related]
50. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
[TBL] [Abstract][Full Text] [Related]
51. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
52. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.
Marinelli L; Balestrino M; Mori L; Puce L; Rosa GM; Giorello L; Currà A; Fattapposta F; Serrati C; Gandolfo C; Abbruzzese G; Trompetto C
BMJ Open; 2017 Sep; 7(9):e016843. PubMed ID: 28882919
[TBL] [Abstract][Full Text] [Related]
53. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
54. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Oreja-Guevara C
Rev Neurol; 2012 Oct; 55(7):421-30. PubMed ID: 23011861
[TBL] [Abstract][Full Text] [Related]
55. [Cannabis medicines in Norway--the basis for approval].
Gramstad L; Sagabråten AS
Tidsskr Nor Laegeforen; 2012 Dec; 132(23-24):2598-9. PubMed ID: 23338087
[No Abstract] [Full Text] [Related]
56. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
[TBL] [Abstract][Full Text] [Related]
57. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
[TBL] [Abstract][Full Text] [Related]
58. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
59. The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.
Russo M; Dattola V; Logiudice AL; Ciurleo R; Sessa E; De Luca R; Bramanti P; Bramanti A; Naro A; Calabrò RS
Medicine (Baltimore); 2017 Nov; 96(46):e8826. PubMed ID: 29145345
[TBL] [Abstract][Full Text] [Related]
60. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
